A federal court has ordered a Texas-based company to stop producing compounded drug products intended to be sterile until the company complies with the Federal Food, Drug, and Cosmetic Act and other requirements, the Food and Drug Administration announced today. The government alleges that Guardian Pharmacy Services distributed purportedly sterile drug products made under unsanitary conditions and in violation of current good manufacturing practice requirements. According to the complaint, the company also made and distributed misbranded drugs because their labels did not include adequate directions for patient use, were false or misleading. In 2017, the FDA received adverse event reports concerning at least 43 patients who received eye injections during cataract surgery of a drug compounded by Guardian.

Related News Articles

Headline
HHS is soliciting input and will meet with vendors Aug. 7-8 to spur innovation in developing new technologies and products to save lives and improve health…
Headline
The Centers for Disease Control and Prevention is working with the U.S. Embassy in the Democratic Republic of the Congo to preposition staff in Goma to rapidly…
Headline
The World Health Organization today declared the Ebola virus disease outbreak in the Democratic Republic of the Congo a public health emergency of…
Headline
The Centers for Medicare…
Headline
CMS anticipates releasing later this summer the feedback it received on potential methodology changes to the overall hospital quality star ratings, the agency…
Headline
The Health Resources and Services Administration yesterday recognized 10 states whose critical access hospitals had the highest quality reporting rates and…